Polylaminin is a molecule developed in Brazil at the Federal University of Rio de Janeiro (UFRJ), emerging from research into extracellular matrix biology led by Tatiana Coelho-Sampaio and collaborators. Its scientific trajectory dates back to the 2000s and gained significant public visibility in the 2020s. Derived from laminin, a protein that plays an important role in the organization of nervous tissue, it has been studied as a biological bridge capable of supporting the reconnection of neural circuits following spinal cord injuries.

Still at an experimental stage, the substance has attracted attention in Brazil and abroad by bringing together basic science, regenerative medicine, and the potential for social impact in a field historically marked by limited therapeutic options. Beyond its possible clinical implications, its development projects an image of Brazil as a producer of sophisticated biomedical knowledge, capable of transforming university research into a subject of international interest while generating hope, public debate, media coverage, and recognition for science produced in Rio de Janeiro.

Presence Indicators:

• The topic has circulated widely in the Brazilian press and in English-language content focused on science and biomedical innovation.
• The research has moved beyond strictly academic circles and entered public debate due to preliminary results in humans and expectations surrounding regulatory approval.
• It is registered in Brazil’s official clinical trials database, reinforcing the institutionalization and public monitoring of the research.
• The case has been cited as an example of Brazilian translational science with the potential for international impact.